CG Pharmaceuticals has reported positive results from their Phase 1b trial of ivaltinostat in combination with capecitabine for metastatic pancreatic cancer treatment. The study demonstrated a manageable safety profile with 65% of patients showing stable disease or no evidence of disease, leading to the advancement of a Phase 2 trial that has already achieved 62% enrollment across 17 U.S. sites.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.